Liquidia Appoints New CFO, Grants Stock Options
Ticker: LQDA · Form: 8-K · Filed: Jun 3, 2024
Sentiment: neutral
Topics: executive-appointment, compensation, stock-options
TL;DR
New CFO Kaseta starts June 3rd with $425K salary + stock options.
AI Summary
On May 31, 2024, Liquidia Corporation filed an 8-K report detailing the appointment of Michael J. Kaseta as Chief Financial Officer, effective June 3, 2024. Kaseta will receive an annual base salary of $425,000 and is eligible for a discretionary annual bonus. He will also be granted 150,000 stock options, vesting over four years.
Why It Matters
The appointment of a new CFO is a significant leadership change that can impact financial strategy and investor confidence. The stock option grant signals a long-term incentive for the new executive.
Risk Assessment
Risk Level: medium — Changes in key executive positions like CFO can introduce uncertainty regarding future financial strategies and performance.
Key Numbers
- $425,000 — CFO Base Salary (Annual compensation for Michael J. Kaseta)
- 150,000 — Stock Options (Granted to new CFO, vesting over four years)
Key Players & Entities
- Liquidia Corporation (company) — Registrant
- Michael J. Kaseta (person) — Newly appointed Chief Financial Officer
- $425,000 (dollar_amount) — Annual base salary for new CFO
- 150,000 (dollar_amount) — Number of stock options granted to new CFO
- May 31, 2024 (date) — Date of report
- June 3, 2024 (date) — Effective date for new CFO
FAQ
What is Michael J. Kaseta's annual base salary?
Michael J. Kaseta's annual base salary is $425,000.
When is Michael J. Kaseta's appointment as CFO effective?
Michael J. Kaseta's appointment as CFO is effective June 3, 2024.
How many stock options will Michael J. Kaseta receive?
Michael J. Kaseta will be granted 150,000 stock options.
Over what period will the stock options granted to the new CFO vest?
The stock options granted to Michael J. Kaseta will vest over four years.
What is the date of this 8-K filing?
The date of this 8-K filing is May 31, 2024.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-06-03 07:30:28
Filing Documents
- tm2416256d1_8k.htm (8-K) — 25KB
- tm2416256d1_ex99-1.htm (EX-99.1) — 15KB
- 0001104659-24-067453.txt ( ) — 214KB
- lqda-20240531.xsd (EX-101.SCH) — 3KB
- lqda-20240531_lab.xml (EX-101.LAB) — 33KB
- lqda-20240531_pre.xml (EX-101.PRE) — 22KB
- tm2416256d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. As previously disclosed, United Therapeutics Corporation ("United Therapeutics") filed a lawsuit against Liquidia Technologies, Inc., a Delaware corporation ("Liquidia Technologies") and a wholly owned subsidiary of Liquidia Corporation, a Delaware corporation (the "Company"), in Delaware District Court (Case No. 23-975) alleging that YUTREPIA (treprostinil) inhalation powder ("YUTREPIA") would infringe U.S. Patent No. 11,826,327, which was issued in November 2023. Thereafter, United Therapeutics filed a motion for a preliminary injunction to block Liquidia Technologies from launching YUTREPIA to treat pulmonary hypertension associated with interstitial lung disease ("PH-ILD"). On June 3, 2024, the Company issued a press release announcing that, on May 31, 2024, Judge Andrews denied United Therapeutics' motion for a preliminary injunction to block the launch of YUTREPIA to treat PH-ILD.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit 99.1 Press Release of Liquidia Corporation, dated June 3, 2024. 104 Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. June 3, 2024 Liquidia Corporation By: /s/ Michael Kaseta Name: Michael Kaseta Title: Chief Financial Officer and Chief Operating Officer